MA31072B1 - Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes - Google Patents

Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes

Info

Publication number
MA31072B1
MA31072B1 MA32013A MA32013A MA31072B1 MA 31072 B1 MA31072 B1 MA 31072B1 MA 32013 A MA32013 A MA 32013A MA 32013 A MA32013 A MA 32013A MA 31072 B1 MA31072 B1 MA 31072B1
Authority
MA
Morocco
Prior art keywords
formula
tetrahydrocyclopenta
modulators
compound
androgen receptor
Prior art date
Application number
MA32013A
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Prabhakar Kondaji Jadhav
Donald Paul Matthews
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31072B1 publication Critical patent/MA31072B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE : FORMULE (I) OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT LE COMPOSÉ AA DE FORMULE (I) EN ASSOCIATION AVEC UN TRANSPORTEUR APPROPRIÉ, UN DILUANT, OU UN EXCIPIENT; ET DES PROCÉDÉS POUR TRAITER DES TROUBLES PHYSIOLOGIQUES, EN PARTICULIER UNE MASSE OSSEUSE RÉDUITE, UNE OSTÉOPOROSE, UNE OSTÉOPÉNIE, OU UNE MASSE OU FORCE MUSCULAIRE RÉDUITE, COMPRENANT L'ADMINISTRATION D'UN COMPOSÉ DE FORMULE (I), OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI.
MA32013A 2006-11-20 2009-06-17 Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes MA31072B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
MA31072B1 true MA31072B1 (fr) 2010-01-04

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32013A MA31072B1 (fr) 2006-11-20 2009-06-17 Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes

Country Status (37)

Country Link
US (1) US7968587B2 (fr)
EP (1) EP2094658B1 (fr)
JP (1) JP5399259B2 (fr)
KR (1) KR101121471B1 (fr)
CN (1) CN101541749B (fr)
AR (1) AR063559A1 (fr)
AT (1) ATE538091T1 (fr)
AU (1) AU2007324046B2 (fr)
BR (1) BRPI0719092B8 (fr)
CA (1) CA2670340C (fr)
CL (1) CL2007003182A1 (fr)
CO (1) CO6190513A2 (fr)
CR (1) CR10802A (fr)
CY (1) CY1112284T1 (fr)
DK (1) DK2094658T3 (fr)
EA (1) EA015627B1 (fr)
EC (1) ECSP099350A (fr)
ES (1) ES2376048T3 (fr)
HK (1) HK1134089A1 (fr)
HR (1) HRP20120032T1 (fr)
IL (1) IL198410A (fr)
JO (1) JO2800B1 (fr)
MA (1) MA31072B1 (fr)
MX (1) MX2009005251A (fr)
MY (1) MY154547A (fr)
NO (1) NO342531B1 (fr)
NZ (1) NZ576296A (fr)
PE (1) PE20081161A1 (fr)
PL (1) PL2094658T3 (fr)
PT (1) PT2094658E (fr)
RS (1) RS52191B (fr)
SI (1) SI2094658T1 (fr)
TN (1) TN2009000189A1 (fr)
TW (1) TWI398438B (fr)
UA (1) UA98777C2 (fr)
WO (1) WO2008063867A2 (fr)
ZA (1) ZA200903096B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2009105214A2 (fr) 2008-02-22 2009-08-27 Radius Health, Inc. Modulateurs sélectifs du récepteur de l'androgène
BRPI0912394A2 (pt) * 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
US8987319B2 (en) 2010-02-04 2015-03-24 Radius Health, Inc. Selective androgen receptor modulators
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US20140113824A1 (en) 2011-05-10 2014-04-24 Bayer Intellectual Property Gmbh Bicyclic (thio)carbonylamidines
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
WO2017223115A1 (fr) 2016-06-22 2017-12-28 Radius Health, Inc. Méthodes ar+ de traitement du cancer du sein
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
KR20230109795A (ko) 2017-01-05 2023-07-20 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
WO2021151905A1 (fr) * 2020-01-27 2021-08-05 Transition Therapeutics (Ireland 2) Limited Composés de tétrahydrocyclopenta[b]indole servant au traitement de maladie rénale
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) * 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) * 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) * 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) * 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
KR100731566B1 (ko) * 1999-10-14 2007-06-22 가켄 세야쿠 가부시키가이샤 테트라히드로퀴놀린 유도체
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
EP2423190A1 (fr) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Composés présentant un antagonisme du récepteur PGD 2
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
US7728150B2 (en) * 2004-03-03 2010-06-01 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
US20090170923A1 (en) * 2004-11-22 2009-07-02 Kristjan Gudmundsson Hcv inhibitors
MX2007006179A (es) 2004-11-23 2007-06-20 Ptc Therapeutics Inc Tetrahidrocarbazoles como agentes activos para inhibir la produccion del factor de crecimiento endotelial vascular por control de la traduccion.
GT200600078A (es) 2005-02-17 2007-04-12 Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquil condensados
BRPI0611705A2 (pt) 2005-06-24 2016-11-16 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (fr) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Utilisation de dérivés d'indole tricycliques pour le traitement de maladies musculaires
BRPI0912394A2 (pt) 2008-05-16 2016-07-26 Lilly Co Eli moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol

Also Published As

Publication number Publication date
BRPI0719092B8 (pt) 2021-05-25
US7968587B2 (en) 2011-06-28
PL2094658T3 (pl) 2012-05-31
AU2007324046A1 (en) 2008-05-29
CN101541749A (zh) 2009-09-23
IL198410A0 (en) 2010-02-17
NZ576296A (en) 2011-11-25
CA2670340C (fr) 2014-05-20
KR20090082229A (ko) 2009-07-29
ECSP099350A (es) 2009-06-30
JP2010510231A (ja) 2010-04-02
TW200827347A (en) 2008-07-01
EP2094658B1 (fr) 2011-12-21
ZA200903096B (en) 2010-07-28
JO2800B1 (en) 2014-03-15
KR101121471B1 (ko) 2012-02-28
CY1112284T1 (el) 2015-12-09
EA015627B1 (ru) 2011-10-31
TWI398438B (zh) 2013-06-11
TN2009000189A1 (en) 2010-10-18
AU2007324046B2 (en) 2012-04-05
RS52191B (en) 2012-10-31
NO20092103L (no) 2009-05-28
EA200970500A1 (ru) 2009-10-30
AR063559A1 (es) 2009-02-04
WO2008063867A2 (fr) 2008-05-29
PE20081161A1 (es) 2008-08-15
CR10802A (es) 2009-07-13
WO2008063867A3 (fr) 2008-07-31
US20100069404A1 (en) 2010-03-18
IL198410A (en) 2013-09-30
BRPI0719092B1 (pt) 2020-08-18
CA2670340A1 (fr) 2008-05-29
EP2094658A2 (fr) 2009-09-02
ES2376048T3 (es) 2012-03-08
SI2094658T1 (sl) 2012-04-30
HRP20120032T1 (hr) 2012-02-29
CO6190513A2 (es) 2010-08-19
CL2007003182A1 (es) 2008-06-27
BRPI0719092A2 (pt) 2013-12-03
ATE538091T1 (de) 2012-01-15
MX2009005251A (es) 2009-08-19
PT2094658E (pt) 2012-02-22
CN101541749B (zh) 2013-03-27
UA98777C2 (en) 2012-06-25
HK1134089A1 (en) 2010-04-16
DK2094658T3 (da) 2012-02-13
JP5399259B2 (ja) 2014-01-29
NO342531B1 (no) 2018-06-11
MY154547A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
MA31072B1 (fr) Composes tetrahydrocyclopenta [b] indole comme modulateurs du recepteur des androgenes
WO2006124447A3 (fr) N-arylpyrrolidines substituees utilisees comme modulateurs selectifs du recepteur des androgenes
WO2009140448A8 (fr) Modulateurs des récepteurs aux androgènes tétrahydrocyclopenta[b]indoles
WO2007002181A3 (fr) Derives tetrahydrocarbazole convenant comme modulateurs du recepteur d'angrogene
MA29791B1 (fr) Composes therapeutiques.
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
JO3019B1 (ar) ثلاثي مستبدل 4،2،1-ثلاثي زولات
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
UA99132C2 (ru) Производные дикарбоновых кислот как агонисты рецепторов s1p1
MA30807B1 (fr) Compositions pharmaceutiques.
EP2966065A3 (fr) Pyrimidines cyclopenta [d] hydroxylées et méthoxylées utilisées en tant qu'inhibiteurs de la protéine kinase akt
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
WO2006070325A3 (fr) Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
RU2008119410A (ru) Диспергируемые таблетки, включающие деферасирокс
MA30604B1 (fr) Agonistes de ep2
CA2360313A1 (fr) Modulateurs selectifs de recepteur de glucocorticoide
CA2360308A1 (fr) Modulateurs selectifs de recepteur de glucocorticoide
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
EP1621198A3 (fr) Dérivés substitués de carbostyril comme agonistes du sous-type du récepteur 5-HT1A
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
MX2007011280A (es) Dipirazoles como farmacos del sistema nervioso central.
WO2006018708A3 (fr) Derives de pyrrolidine utilises en tant qu'antagonistes des recepteurs muscariniques
AU2003214535A8 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
MX2007005824A (es) Agonistas y antagonistas del receptor de somatostatina.